$15.34
4.07% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
NL0010696654
Symbol
QURE
Sector
Industry

uniQure N.V. Stock price

$15.34
+2.53 19.75% 1M
-0.06 0.39% 6M
-2.32 13.14% YTD
+10.09 192.19% 1Y
-49.90 76.49% 5Y
-16.99 52.55% 10Y
+0.73 5.00% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.65 4.07%
ISIN
NL0010696654
Symbol
QURE
Sector
Industry

Key metrics

Market capitalization $875.43m
Enterprise Value $964.67m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 47.76
P/S ratio (TTM) P/S ratio 43.34
P/B ratio (TTM) P/B ratio 25.97
Revenue growth (TTM) Revenue growth 6.43%
Revenue (TTM) Revenue $20.20m
EBIT (operating result TTM) EBIT $-167.04m
Free Cash Flow (TTM) Free Cash Flow $-167.40m
Cash position $409.01m
EPS (TTM) EPS $-4.09
P/E forward negative
P/S forward 29.84
EV/Sales forward 32.88
Short interest 13.80%
Show more

Is uniQure N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

uniQure N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a uniQure N.V. forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a uniQure N.V. forecast:

Buy
86%
Hold
14%

Financial data from uniQure N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
20 20
6% 6%
100%
- Direct Costs 9.30 9.30
55% 55%
46%
11 11
884% 884%
54%
- Selling and Administrative Expenses 49 49
31% 31%
241%
- Research and Development Expense 136 136
27% 27%
673%
-153 -153
39% 39%
-755%
- Depreciation and Amortization 15 15
21% 21%
72%
EBIT (Operating Income) EBIT -167 -167
36% 36%
-827%
Net Profit -218 -218
27% 27%
-1,077%

In millions USD.

Don't miss a Thing! We will send you all news about uniQure N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

uniQure N.V. Stock News

Neutral
GlobeNewsWire
3 days ago
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V.
Neutral
GlobeNewsWire
12 days ago
~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass.
Positive
Seeking Alpha
17 days ago
uniQure recently divested from its Lexington facility to Genezen and freed $25 million while significantly reducing its operating costs. At the same time, AMT-130 has received the FDA's Breakthrough Therapy, RMAT, Fast-Track, and Orphan Drug status with Accelerated Approval via cUHDRS. Similarly, QURE is building MRI-guided infusion centers, payer-access teams, and a US Center of Excellence net...
More uniQure N.V. News

Company Profile

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Head office Netherlands
CEO Matt Kapusta
Employees 209
Founded 2012
Website www.uniqure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today